Find out which option is the best for you. The DSM-5-TR outlines specific criteria to help professionals diagnose generalized ...

A new Macquarie University study suggests that instead of relying on the 'bible' of mental health diagnosis, we need a ...

In the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), mood disorders (affective disorders) are categorized as either depressive disorders or bipolar and related ...

In addition, first-degree biological relatives of people with MDD are 1.5 to 3 times more likely to develop MDD than the general ... for Evaluating DSM-IV Psychiatric Disorders and the Mental ...

Depression is a mood disorder with a group of symptoms including constant sadness or lack of interest in life. There are a lot of signs of depression, but you may not have them all. How intense ...

However, depression is a highly heterogeneous condition (i.e. there are more than 200 combinations of DSM-5-TR depressive symptoms to correspond to a depression diagnosis). Limited research to date ...

You can experience visual and auditory hallucinations with bipolar disorder. They can occur during mania or depressive episodes ... Manual of Mental Disorders (DSM-5). Hallucinations do often ...

This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when ...

Bipolar disorders ... of Mental Disorders (DSM-IV). [1] These subtypes of bipolar disorders cover a spectrum of severities, frequencies, and durations of manic and depressive symptoms.

Objective To assess whether physically active yoga is superior to waitlist control, treatment as usual and attention control in alleviating depressive symptoms ... diagnosed mental disorder according ...

The Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which shuns the term addiction ... as can an increased desire for privacy. Behavior in general can become unpredictable, and ...

Neumora's lead asset, Navacaprant, shows weak efficacy in phase 2 trial. Read why we are not optimistic about NMRA's ...